Antagonism by growth hormone of insulin-sensitive hexose transport in 3T3-F442A adipocytes. 1989

M S Silverman, and D C Mynarcik, and R E Corin, and H C Haspel, and M Sonenberg
Memorial Sloan-Kettering Cancer Center, Cornell University Medical College, New York, New York 10021.

We have studied the effects of GH on basal and insulin-stimulated hexose transport by 3T3-F442A adipocytes in a hormonally defined serum-free medium. Adipocytes preincubated in defined medium exhibit a low level of hexose transport which is acutely (15 min) stimulated (greater than 5-fold) by insulin (EC50, 0.1-0.2 nM). GH has acute (15-45 min) insulin-mimetic (greater than 2-fold) and chronic (4-48 h) diabetogenic (50-80%) effects on basal and insulin-stimulated hexose transport. The insulin-mimetic effect of GH has a higher EC50 (2 nM) than its diabetogenic effect (EC50, 0.2 nM). Chronic GH exposure decreases the maximal responsiveness (50-80%) and the acute sensitivity (approximately 2-fold) of hexose transport to insulin. Insulin-stimulated transport is more (approximately 5-fold) sensitive to the diabetogenic effect of GH than is basal transport. Insulin binding and degradation were not altered by chronic exposure to GH. The diabetogenic effect of GH may occur at a postinsulin binding level.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007329 Insulin Antagonists Compounds which inhibit or antagonize the biosynthesis or action of insulin. Antagonists, Insulin
D007700 Kinetics The rate dynamics in chemical or physical systems.
D002454 Cell Differentiation Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs. Differentiation, Cell,Cell Differentiations,Differentiations, Cell
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003837 Deoxy Sugars Sugars that in which one or more hydroxyl groups of the pyranose or furanose ring is substituted by hydrogen. Deoxy Sugar,Sugar, Deoxy,Sugars, Deoxy
D003847 Deoxyglucose 2-Deoxy-D-arabino-hexose. An antimetabolite of glucose with antiviral activity. 2-Deoxy-D-glucose,2-Deoxyglucose,2-Desoxy-D-glucose,2 Deoxy D glucose,2 Deoxyglucose,2 Desoxy D glucose
D000273 Adipose Tissue Specialized connective tissue composed of fat cells (ADIPOCYTES). It is the site of stored FATS, usually in the form of TRIGLYCERIDES. In mammals, there are two types of adipose tissue, the WHITE FAT and the BROWN FAT. Their relative distributions vary in different species with most adipose tissue being white. Fatty Tissue,Body Fat,Fat Pad,Fat Pads,Pad, Fat,Pads, Fat,Tissue, Adipose,Tissue, Fatty
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001693 Biological Transport, Active The movement of materials across cell membranes and epithelial layers against an electrochemical gradient, requiring the expenditure of metabolic energy. Active Transport,Uphill Transport,Active Biological Transport,Biologic Transport, Active,Transport, Active Biological,Active Biologic Transport,Transport, Active,Transport, Active Biologic,Transport, Uphill

Related Publications

M S Silverman, and D C Mynarcik, and R E Corin, and H C Haspel, and M Sonenberg
August 1991, Metabolism: clinical and experimental,
M S Silverman, and D C Mynarcik, and R E Corin, and H C Haspel, and M Sonenberg
April 1998, Biochemical and biophysical research communications,
M S Silverman, and D C Mynarcik, and R E Corin, and H C Haspel, and M Sonenberg
August 1988, Endocrinology,
M S Silverman, and D C Mynarcik, and R E Corin, and H C Haspel, and M Sonenberg
April 2013, Lipids in health and disease,
M S Silverman, and D C Mynarcik, and R E Corin, and H C Haspel, and M Sonenberg
January 1985, Diabetologia,
M S Silverman, and D C Mynarcik, and R E Corin, and H C Haspel, and M Sonenberg
January 1988, Biochemistry,
M S Silverman, and D C Mynarcik, and R E Corin, and H C Haspel, and M Sonenberg
December 2007, Endocrine journal,
M S Silverman, and D C Mynarcik, and R E Corin, and H C Haspel, and M Sonenberg
July 1985, The Journal of biological chemistry,
M S Silverman, and D C Mynarcik, and R E Corin, and H C Haspel, and M Sonenberg
January 2004, British journal of pharmacology,
M S Silverman, and D C Mynarcik, and R E Corin, and H C Haspel, and M Sonenberg
January 1999, Sheng wu hua xue yu sheng wu wu li xue bao Acta biochimica et biophysica Sinica,
Copied contents to your clipboard!